News List

Gilead's Veklury has been approved:Veklury is the First Approved Treatment Option for COVID-19 in the European Union

At present,The COVID-19 epidemic continues to spread rapidly around the world. As of 01am, July 04,

Announcement on the extension of CPHI North America 2020 in September

Dear Customers,Unfortunately, we have to cancel the plan for our participation in the CPHI North Ame

New medicine for insomnia! Eisai double-acting orexin receptor antagonist Dayvigo (lemborexant) is launched in the US!

Japanese pharmaceutical company Eisai recently announced the launch of Dayvigo (lemborexant), a new

The first c-Met inhibitor approved by the FDA to market

On May 6, the FDA approved the listing of Novartis Tabrecta (capmatinib) for the treatment of patien

The cortisol synthesis inhibitor Isturia developed by Recordati has been approved by the European Union!

On January 16, 2020, the Italian pharmaceutical company Recordati recently announced that the Europe

Fapilavir completes clinical research and shows good clinical efficacy

On March 17th, the State Council's joint prevention and control mechanism held a press conferenc

Migraine relieved within 1 hour, FDA approves new oral medication

2020.02.27, Biohaven announced that the US FDA has approved the company's CGRP receptor inhibito

Insomnia and schizophrenia innovative treatments approved

Dayvigo (lembroexant) developed by Eisai is an orexin receptor antagonist. Orexin is a neuropeptide

First oral small molecule CGRP receptor inhibitor approved today for the treatment of migraine

Recently, the US FDA announced that it has approved the listing of the calcitonin gene-related pepti

Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma

Novartis recently announced topline results from its pivotal global Phase III LUSTER-11and LUSTER-22